Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 20.86 USD -3.02% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Kiniksa Pharmaceuticals Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-27.8
Current
-25.8
Median
3.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-27.8
=
Enterprise Value
1.3B USD
/
EBIT
-45.6m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
BM
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Average EV/EBIT: 22.5
Negative Multiple: -27.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 708.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26.5
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
30.4
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.9
10%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.2
17%
0.8
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 239.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
31.4
2-Years Forward
EV/EBIT
26.5
3-Years Forward
EV/EBIT
13.5